Skip to main content

FENOLES DE ORIGEN NATURAL EN EL TRATAMIENTO Y PREVENCION DE LA ENFERMEDAD INFLAMATORIA INTESTINAL. SCREENING VIRTUAL, SELECCION Y ENSAYOS FARMACOLOGICOS

SAF2009-13059-C03-01

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2009
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Subdirección General de Proyectos de Investigación
Beneficiary centre UNIVERSITAT DE VALÈNCIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Beneficial Effect of Shikonin on Experimental Colitis Induced by Dextran Sulfate Sodium in Balb/C Mice

  • Andújar Pérez, Isabel
  • Rios, José Luis
  • Giner, Rosa María
  • Cerda, José Miguel
  • Recio, María del Carmen
[EN] The naphthoquinone shikonin, a major component of the root of Lithospermum erythrorhizon, now is studied as an anti-inflammatory agent in the treatment of ulcerative colitis (UC). Acute UC was induced in Balb/C mice by oral administration of 5% dextran sodium sulfate (DSS). The disease activity index was evaluated, and a histologic study was carried out. Orally administered shikonin reduces induced UC in a dose-dependent manner, preventing the shortening of the colorectum and decreasing weight loss by 5% while improving the appearance of feces and preventing bloody stools. The disease activity index score was much lower in shikonin-treated mice than in the colitic group, as well as the myeloperoxidase activity. The expression of cyclooxygenase-2 was reduced by 75%, activation of NF-kappa B was reduced by 44%, and that of pSTAT-3 by 47%, as well as TNF-alpha, IL-1 beta, and IL-6 production. Similar results were obtained in primary macrophages culture. This is the first report of shikonin's ability to attenuate acute UC induced by DSS. Shikonin acts by blocking the activation of two major targets: NF-kappa B and STAT-3, and thus constitutes a promising potential therapeutic agent for the management of the inflammatory bowel disease., This work was supported by the Spanish Government (SAF2009-13059-C03-01). I. Andujar is grateful for a fellowship from the Generalitat Valenciana, Grant BFPI/2008/040.